Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

This publication has 30 references indexed in Scilit:

• Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
  Journal of Clinical Oncology, 2020
• Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma
  Clinical Genitourinary Cancer, 2020
• Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214
  European Urology, 2019
• Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review
  Expert Review of Molecular Diagnostics, 2019
• Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?
  Clinical Genitourinary Cancer, 2018
• Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
  New England Journal of Medicine, 2018
• On comparing 2 correlated C indices with censored survival data
  Statistics in Medicine, 2017
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
  New England Journal of Medicine, 2015
• External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
  The Lancet Oncology, 2013
• Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
  Journal of Clinical Oncology, 2009